Company / R&D Expense
ROCKET PHARMACEUTICALS, INC. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$171.2M
FY2025
5-year range
$57.9M / $171.2M
FY2021-FY2025
Trend
+3.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 5 consecutive years, from $53M in FY2020 to $171M in FY2025.
Based on SEC 10-K filings.
$171M in FY2025 with a 5-year CAGR of +26.3%.
Improved from $125M to $171M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +17.5%
- 5-Year CAGR
- +26.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- ROCKET PHARMACEUTICALS, INC.'s r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +26.3%, indicating consistent growth.
- In FY2025, r&d expense increased 3.4% year-over-year.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $171.2M | +3.4% |
| FY2024 | $165.6M | +32.0% |
| FY2023 | $125.5M | +19.0% |
| FY2022 | $105.4M | +82.1% |
| FY2021 | $57.9M | +8.7% |
| FY2020 | $53.3M | +0.0% |
| FY2019 | $53.3M | +788.7% |
| FY2018 | $6.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026